You wouldn’t know that from the immediate reaction to yesterday’s announcement. Axios’ Neal Rothschild notes that of the 20 most-engaged stories on social media about the Johnson & Johnson pause, just two headlines included the context that the blood clots were rare occurrences, according to data from NewsWhip. That’s part of the reason critics feared the FDA was overreacting, allowing a very small number of adverse events to potentially undermine a very large number of people’s confidence in all-important vaccines. But that criticism is missing some context of its own. One woman died from her blood clot, suggesting a potentially serious risk. The number of incidents will likely grow, now that doctors and regulators are looking for them more closely. The FDA also said doctors need to be highly attuned to a vaccine-specific risk of blood clots because the standard treatment for blood clots can make this particular type of clot worse.